Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Baminercept alfa 1, LT beta, Baminercept alfa 2, Baminercept alfa 3, Baminercept alfa 4, Baminercept alfa 5, Baminercept alfa (BG9924), Baminercept alfa
BG9924 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | subcutaneous administration of placebo given for 12 weeks |
| One Dose | EXPERIMENTAL | BG9924 - dosage level administered as per Biogen Idec protocol |
| Second Dose | EXPERIMENTAL | BG9924 - dosage level administered as per Biogen Idec protocol |
| Third Dose | EXPERIMENTAL | BG9924 - dosage level administered as per Biogen Idec protocol |
| Fourth Dose | EXPERIMENTAL | BG9924 - dosage level administered as per Biogen Idec protocol |
| Fifth Dose | EXPERIMENTAL | BG9924 - dosage level administered as per Biogen Idec protocol |
| Name | Type | Description |
|---|---|---|
| Baminercept alfa 1 | BIOLOGICAL | experimental - one dose level |
| Placebo | BIOLOGICAL | Placebo comparator |
| Baminercept alfa 2 | BIOLOGICAL | experimental - second dose level |
| Baminercept alfa 3 | BIOLOGICAL | experimental - third dose level |
| Baminercept alfa 4 | BIOLOGICAL | experimental - fourth dose level |
| Baminercept alfa 5 | BIOLOGICAL | experimental - fifth dose level |
| BG9924 | DRUG | - |
Key Inclusion Criteria: * Diagnosis of RA (functional class I - III) * Stable dose of MTX * Inadequate response to at least one conventional DMARD therapy Key Exclusion Criteria: * Serious local infection or systemic infection * History (Hx) of recurrent infections requiring oral or parenteral an...
Top 20 of 31 competitors
BG9924 is an investigational small molecule developed by Biogen Inc. (ticker BIIB) for the treatment of rheumatoid arthritis. It is a Phase 2 drug candidate in the immunology therapeutic area. It has been studied in combination with methotrexate in adults with active rheumatoid arthritis.
BG9924 is being developed for rheumatoid arthritis, an inflammatory joint disease. The clinical program studied BG9924 in combination with methotrexate in adults aged 18 years and older with active rheumatoid arthritis. It is investigational and has not been established as a marketed treatment.
BG9924 targets LT beta receptor, also known as LTßR, a cell surface receptor. LTßR is the molecular target of this small molecule. Targeting this receptor places BG9924 in the immunology space, where it was evaluated for rheumatoid arthritis in combination with methotrexate.
BG9924 is developed by Biogen Inc., which trades under the ticker BIIB. Biogen sponsored the clinical program for BG9924, including the Phase 2 study conducted in the United States and Poland in patients with active rheumatoid arthritis.
BG9924 is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. The completed study was a randomized, double-blind, dose-escalating Phase 2 trial of BG9924 in combination with methotrexate in active rheumatoid arthritis.
BG9924 has been studied in one Phase 2 trial, NCT00292422, titled Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis. The trial enrolled 50 participants, was randomized and double-blind, and was conducted in the United States and Poland. It is now completed.